HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NIH Office Of Dietary Supplements Keeps Tabs On What DSHEA Wrought For US Consumers

Marking 25 Years, ODS Staff Note Room For Improvement In Supplement Market

Executive Summary

While working to improve the quality of VMS products available in the US and to provide information on the products to consumers, the ODS doesn’t have authority to impose change on the industry or in the marketplace.

You may also be interested in...

Compiling Pre-DSHEA Ingredient List Relies On Bridging FDA-Industry Gap

"Nobody said these are easy questions, if they were they would have been answered a long time ago," says Steve Tave, director of FDA's Office of Dietary Supplement Programs. Industry stakeholders at a public meeting recommend a reasonable threshold for evidence that verifies a dietary ingredient was available in the US before Congress passed DSHEA.

Ordering Starts For Free OTC COVID-19 Tests; USPS Deliveries Expected Within Two Weeks

US consumers can order up to four rapid antigen tests per household through USPS website, or a phone hotline coming soon. Biden administration, which is working to buy another 500m tests soon, notes more OTC tests are becoming available through an accelerated pathway to support FDA reviews of for emergency use authorizations of tests with potential for large-scale manufacturing.

Record Number Of Mergers Forces US Regulatory Agencies’ Hand On Updating Enforcement Guides

Chairwoman Lina Khan says concerns about impact on consumer product markets from mergers prompted FTC, working with DoJ, to seek public input on modernizing federal merger guidelines to better detect and prevent illegal, anticompetitive deals in current markets.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts